Last updated: September 7, 2026
Cefepime hydrochloride and enmetazobactam, marketed as Exblifep, is a hospital-administered beta-lactam/beta-lactamase inhibitor combination developed for complicated urinary tract infections, including acute pyelonephritis. The U.S. Food and Drug Administration approved Exblifep in February 2024 for adults with complicated urinary tract infections caused by susceptible Gram-negative bacteria, including infections involving extended-spectrum beta-lactamase-producing organisms.[1]
The product has commercial value as a targeted hospital antibiotic, but its revenue ceiling is constrained by antimicrobial-stewardship controls, intravenous administration, competition from established reserve antibiotics, and limited public-company disclosure. Its financial trajectory is more likely to follow a gradual formulary-adoption curve than a rapid primary-care pharmaceutical launch.
What is Exblifep and how does it work?
Exblifep combines cefepime hydrochloride, a fourth-generation cephalosporin, with enmetazobactam, a novel beta-lactamase inhibitor. The approved U.S. dose is 2 grams of cefepime and 0.5 grams of enmetazobactam administered intravenously every eight hours, with dosage adjustment for renal impairment.[1]
| Product attribute |
Details |
| Brand name |
Exblifep |
| Active ingredients |
Cefepime hydrochloride and enmetazobactam |
| Administration |
Intravenous infusion |
| U.S. sponsor |
Allecra Therapeutics |
| U.S. NDA |
217350 |
| U.S. approval |
February 13, 2024 |
| Initial indication |
Complicated urinary tract infections, including acute pyelonephritis |
| Primary target |
Gram-negative bacterial infections, including ESBL-producing pathogens |
| Commercial setting |
Hospitals and hospital-linked outpatient infusion settings |
Enmetazobactam is designed to inhibit class A beta-lactamases, including extended-spectrum beta-lactamases. The combination preserves cefepime activity against selected resistant organisms that would otherwise hydrolyze the antibiotic.
The product does not cover every important carbapenem-resistant mechanism. Activity against organisms producing metallo-beta-lactamases, such as NDM enzymes, remains a major limitation for the wider resistant-infection market.
What FDA regulatory status and exclusivity does Exblifep have?
Exblifep received FDA approval through the 505(b)(1) new drug application pathway. The FDA approval was supported by the phase 3 ALLIUM study, which evaluated cefepime-enmetazobactam against piperacillin-tazobactam in adults with complicated urinary tract infections.[1]
The product also received Qualified Infectious Disease Product status under the Generating Antibiotic Incentives Now provisions of the Food, Drug, and Cosmetic Act. QIDP designation can provide priority review and five years of additional regulatory exclusivity beyond otherwise applicable Hatch-Waxman exclusivity.[2]
| Regulatory protection |
Commercial effect |
| New drug approval |
Creates FDA approval rights for the branded combination and approved indication |
| QIDP designation |
Adds five years of exclusivity to qualifying regulatory exclusivity |
| Intravenous hospital product |
Limits substitution to pharmacy and hospital procurement channels |
| Combination product |
Supports protection for the cefepime-enmetazobactam regimen rather than cefepime alone |
A QIDP designation does not create a permanent barrier to generic entry. Generic applicants may still challenge patents through Paragraph IV certifications, and regulatory exclusivity does not prevent all patent-based challenges.
The principal U.S. approval date is February 13, 2024. A standard five-year new chemical entity period would extend through February 2029 if applicable to the relevant active ingredient. QIDP-related exclusivity can extend the relevant period beyond that date. The precise generic-entry date depends on the active-ingredient classification, Orange Book listings, patent term adjustments, pediatric exclusivity, and litigation outcomes.
What patents protect cefepime hydrochloride and enmetazobactam?
The commercially relevant intellectual-property estate is expected to include several layers:
- Composition and chemical-process patents covering enmetazobactam.
- Pharmaceutical-composition patents covering the cefepime-enmetazobactam combination.
- Dosing and treatment patents for resistant Gram-negative infections.
- Manufacturing and formulation rights concerning a stable intravenous product.
- Regulatory exclusivity tied to the approved drug application.
Cefepime itself is a mature generic antibiotic. The core commercial barrier therefore does not come from cefepime composition rights. Value is concentrated in enmetazobactam, the combination formulation, manufacturing know-how, and the approved clinical use.
What is the Orange Book status of Exblifep?
The FDA Orange Book is the controlling public source for approved-product patent and exclusivity listings. The FDA approval record identifies Exblifep under NDA 217350, but the existence and scope of any current patent listings must be assessed against the live Orange Book entry rather than inferred from the approval announcement.[1,3]
For generic-entry analysis, the relevant questions are:
- Whether patents covering enmetazobactam are listed against NDA 217350.
- Whether combination-product patents are listed.
- Whether method-of-use patents cover only the approved indication or broader resistant-pathogen treatment.
- Whether listed patents expire before or after QIDP-related regulatory exclusivity.
- Whether a generic applicant would need to challenge formulation, use, or active-ingredient claims.
The strongest blocking position would combine long-dated enmetazobactam composition rights with listed combination and formulation patents. A portfolio limited to method-of-use claims would be more vulnerable to a non-infringing label strategy.
When does Exblifep lose exclusivity?
The effective U.S. loss-of-exclusivity date is not determined by the 2024 approval date alone.
| Milestone |
Timing or status |
| FDA approval |
February 13, 2024 |
| Potential five-year NCE period |
Approximately through February 2029, if applicable |
| QIDP extension |
Five additional years for qualifying exclusivity |
| Earliest practical generic filing window |
Potentially before full exclusivity expiration, depending on ANDA eligibility |
| Generic launch |
Dependent on patent certifications, litigation, settlement terms, and regulatory exclusivity |
A Paragraph IV ANDA may be filed before patent expiry. The first applicant to submit a substantially complete Paragraph IV certification can receive 180-day generic exclusivity if statutory requirements are met. A patent lawsuit filed within 45 days of receiving notice can trigger a 30-month stay of FDA approval, subject to statutory exceptions and litigation outcomes.[4]
Because Exblifep is an intravenous hospital product, an authorized generic or licensed generic arrangement could materially affect the commercial impact of later ANDA entry. Hospital purchasers can switch products faster than retail patients, but adoption still depends on pharmacy-and-therapeutics committee review, antimicrobial-stewardship approval, supply continuity, and microbiology data.
What market is Exblifep targeting?
Exblifep targets serious Gram-negative infections where resistance reduces the usefulness of standard cephalosporins and creates pressure to use carbapenems or newer reserve antibiotics.
The main commercial segments are:
- Complicated urinary tract infections.
- Acute pyelonephritis.
- Hospitalized patients with suspected ESBL-producing pathogens.
- Patients requiring a carbapenem-sparing option.
- Hospitals seeking additional treatment capacity for resistant Enterobacterales.
The U.S. market is clinically important but relatively narrow. Intravenous antibiotics are administered in hospitals, infusion centers, or structured outpatient programs. Product use is controlled by infectious-disease specialists and hospital pharmacists rather than broad prescriber demand.
Exblifep competes with:
| Product |
Active ingredients |
Main competitive position |
| Exblifep |
Cefepime/enmetazobactam |
ESBL-focused cephalosporin-beta-lactamase inhibitor |
| Avycaz |
Ceftazidime/avibactam |
Broad hospital use, including selected resistant pathogens |
| Zerbaxa |
Ceftolozane/tazobactam |
Complicated urinary and intra-abdominal infections; activity against selected Pseudomonas |
| Vabomere |
Meropenem/vaborbactam |
Carbapenem-based option, particularly for KPC-producing organisms |
| Fetroja |
Cefiderocol |
Broad resistant Gram-negative positioning, including some carbapenem-resistant organisms |
| Generic cefepime |
Cefepime alone |
Low-cost standard therapy where beta-lactamase-mediated resistance is not present |
Exblifep's principal differentiation is the combination of cefepime's established spectrum and enmetazobactam's activity against selected class A beta-lactamases. Its limitation is that it is not a universal replacement for carbapenems, ceftazidime-avibactam, or cefiderocol.
How strong is the patent estate for Exblifep?
The patent estate is commercially meaningful but technically narrower than estates protecting chronic-care drugs or biologics.
Strengths
- The active combination includes a newer beta-lactamase inhibitor.
- Hospital products can benefit from formulation and manufacturing claims.
- QIDP status extends regulatory protection.
- Generic substitution requires development of a sterile intravenous combination product.
- Clinical positioning may support method-of-use claims directed to resistant pathogens.
Weaknesses
- Cefepime is already generic.
- The treatment population is concentrated in a limited hospital market.
- Method-of-use patents can be challenged through label carve-outs.
- Competing reserve antibiotics already have hospital contracts and clinical familiarity.
- Beta-lactamase biology can limit the product's use against non-covered resistance mechanisms.
The highest-value patent claims are likely those that cover enmetazobactam itself, stable cefepime-enmetazobactam formulations, and manufacturing processes that are difficult to reproduce at commercial scale. Use claims alone would provide less durable protection.
Which companies are commercializing or challenging Exblifep?
Allecra Therapeutics developed Exblifep and holds the central commercial rights associated with the product. Commercialization outside the core development organization has involved regional partnering and specialty-pharmaceutical infrastructure rather than the broad sales force used for mass-market medicines.
No major public Paragraph IV challenge or generic litigation campaign has been established in the cited FDA approval materials. The absence of a publicly identified challenge does not eliminate future ANDA activity. The relevant filing window will be shaped by the product's Orange Book patents and applicable regulatory exclusivity.
Potential challengers include:
- Large generic manufacturers with sterile injectable capacity.
- Hospital-injectable specialists.
- International companies seeking regional rights.
- Existing suppliers of generic cefepime that can add beta-lactamase-inhibitor manufacturing capability.
The most credible commercial threat may emerge from a licensed generic or hospital-focused injectable company rather than from a conventional high-volume oral-generic manufacturer.
What licensing deals affect Exblifep's commercial outlook?
Exblifep's commercial model depends heavily on licensing and regional commercialization because Allecra is a specialty anti-infective company rather than a large diversified pharmaceutical manufacturer.
A licensing arrangement can improve:
- Hospital contracting capacity.
- Government procurement access.
- Distribution reliability.
- Regulatory execution in Europe and other jurisdictions.
- Post-launch pharmacovigilance and medical-affairs coverage.
It can also reduce the originating company's share of product revenue through royalties, milestones, transfer pricing, or profit-sharing. Public disclosures do not provide a complete, product-level revenue bridge for Exblifep.
What is the financial trajectory for cefepime-enmetazobactam?
Exblifep's revenue curve is likely to have four stages.
1. Launch and formulary placement
The first phase is driven by FDA approval, hospital formulary review, infectious-disease education, and initial contract wins. Sales are likely to be concentrated in academic hospitals, high-volume tertiary centers, and institutions with high ESBL prevalence.
2. Clinical conversion
Revenue growth depends on conversion from carbapenems, piperacillin-tazobactam, and competing beta-lactamase-inhibitor products. This conversion requires microbiology support, stewardship protocols, and evidence that the drug reduces carbapenem use without compromising outcomes.
3. Procurement expansion
The product can expand through group purchasing organizations, government hospitals, integrated delivery networks, and outpatient parenteral antibiotic therapy channels. Pricing will face pressure from hospital tenders and competitive contracting.
4. Mature and post-exclusivity sales
Before generic entry, sales can remain defensible if the product secures guideline inclusion and hospital protocols. After generic entry, unit volume may remain stable while net price falls sharply. Injectable hospital generics often produce rapid price erosion when multiple suppliers enter.
Public financial statements do not provide a reliable standalone Exblifep revenue series or an independently verified peak-sales forecast. The financial case is therefore based on market access and utilization rather than reported product revenue.
What generic launch risks exist?
The main generic-entry risks are:
- A successful Paragraph IV challenge to composition or formulation patents.
- A non-infringing generic label that removes patented method-of-use language.
- An authorized generic launch before full patent expiry.
- Hospital purchasing decisions based primarily on price.
- Manufacturing competition from established sterile-injectable suppliers.
- Clinical evidence showing narrower-than-expected use against local resistance patterns.
The main delay factors are complex sterile manufacturing, limited initial market size, patent litigation costs, and the need to demonstrate pharmaceutical equivalence for a combination injectable product.
What geographic markets matter?
The United States is the most important early commercial market because of its high spending on hospital anti-infectives and the FDA's QIDP framework. Europe is strategically relevant because antimicrobial resistance and hospital procurement create demand for new beta-lactamase inhibitor combinations, although national reimbursement and tender systems can compress price.
Other opportunities may exist in:
- Japan and South Korea, where hospital antibiotic stewardship is advanced.
- Gulf markets with high private-hospital purchasing.
- Latin America, where ESBL prevalence can be high but reimbursement is uneven.
- India and Southeast Asia, where resistance burden is substantial but local generic competition can be intense.
Geographic value will depend on local patent rights, regulatory approval, reimbursement, and the presence of procurement-based pricing.
Key Takeaways
- Exblifep is a 2024 FDA-approved intravenous combination of cefepime hydrochloride and enmetazobactam.
- Its initial value proposition is treatment of complicated urinary tract infections caused by susceptible resistant Gram-negative organisms.
- QIDP status provides important regulatory protection, but it does not eliminate Paragraph IV patent risk.
- The commercial market is specialized, hospital-based, and controlled by antimicrobial-stewardship programs.
- Cefepime is generic, so durable value is concentrated in enmetazobactam, the combination product, formulation, manufacturing, and clinical-use claims.
- Public disclosures do not establish a reliable standalone revenue history or validated peak-sales forecast.
- The most important financial variables are formulary adoption, hospital contracting, resistance-driven utilization, pricing, and the timing of generic entry.
- Exblifep is more likely to produce a measured specialty-antibiotic revenue trajectory than blockbuster-scale primary-care sales.
FAQs
Is cefepime-enmetazobactam a carbapenem replacement?
It is a carbapenem-sparing option for selected infections caused by susceptible Gram-negative organisms, especially certain ESBL-producing Enterobacterales. It is not a universal replacement for carbapenems because activity depends on the resistance mechanism and pathogen.
Does Exblifep treat metallo-beta-lactamase-producing bacteria?
Enmetazobactam is not designed to inhibit metallo-beta-lactamases such as NDM. Treatment of those infections generally requires a different antimicrobial strategy based on susceptibility results.
Is Exblifep available as an oral antibiotic?
No. Exblifep is an intravenous product. Its commercial use is concentrated in hospitals and structured outpatient infusion settings.
What is the biggest commercial threat to Exblifep?
The largest threat is competition from established hospital antibiotics, particularly ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol, and low-cost generic agents used when susceptibility permits.
Can a generic company copy Exblifep before patent expiration?
A generic company may file an ANDA with appropriate patent certifications before patent expiration, but FDA approval and commercial launch depend on regulatory exclusivity, listed patents, Paragraph IV litigation, settlement terms, and any applicable 30-month stay.
References
-
U.S. Food and Drug Administration. (2024). Exblifep (cefepime and enmetazobactam) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Qualified infectious disease product designation and exclusivity provisions. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and patent certifications under the Hatch-Waxman Amendments. FDA.
